Sulforidazine
Typical antipsychotic medication
![]() | |
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.035.274 ![]() |
Chemical and physical data | |
Formula | C21H26N2O2S2 |
Molar mass | 402.57 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Sulforidazine (Imagotan, Psychoson, Inofal) a typical antipsychotic and a metabolite of thioridazine; it and mesoridazine are more potent than the parent compound, whose pharmacological effects are believed by some to be largely due to its metabolism into sulforidazine and mesoridazine.[1]
Synthesis
[edit]![](http://upload.wikimedia.org/wikipedia/commons/thumb/6/68/Sulforidazine_synthesis.svg/500px-Sulforidazine_synthesis.svg.png)
2-bromo-2'-amino-4'-methylsulphonyl-diphenyl Sulphide, CID:43448246 (1) 2-bromo-2'-acetamino-4'-methylsulphonyl diphenylsulphide (2) 2-(2-Chloroethyl)-1-Methylpiperidine [50846-01-0] (3)
References
[edit]- ^ Niedzwiecki DM, Mailman RB, Cubeddu LX (March 1984). "Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors". Journal of Pharmacology and Experimental Therapeutics. 228 (3): 636–9. PMID 6707914.
- ^ Morrow, Ryan J.; Millership, Jeff S.; Collier, Paul S. (2005). "Facile Syntheses of the Three Major Metabolites of Thioridazine". Helvetica Chimica Acta. 88 (5): 962–967. doi:10.1002/hlca.200590089.
- ^ FR1363683 idem Bruschweiler Conrad, Schwarb Gustav, Winkler Hans, Renz Jany, U.S. patent 3,314,948 (1967 to Sandoz Ltd).
|
D1-like |
| ||||||
---|---|---|---|---|---|---|---|
D2-like |
| ||||||
H1 |
| ||||
---|---|---|---|---|---|
H2 |
| ||||
H3 |
| ||||
H4 |
| ||||
Classes | |
---|---|
Antidepressants (Tricyclic antidepressants (TCAs)) |
|
Antihistamines |
|
Antipsychotics |
|
Anticonvulsants | |
Anticholinergics | |
Others |
|
![]() | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |